导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 7.83% | 937/4587 |
| 近一周 | -1.68% | 2408/5248 |
| 近一月 | -0.83% | 938/5205 |
| 近一季 | 2.45% | 556/5018 |
| 近半年 | 8.64% | 629/4725 |
| 近一年 | 10.24% | 1088/4241 |
| 近两年 | 46.35% | 1550/2862 |
| 近三年 | 33.09% | 925/2171 |
| 成立以来 | 597.45% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.89% 3964/4961 |
18.12% 1416/5312 |
- - |
- - |
| 2025 | 16.59% 2438/4813 |
-0.08% 2052/3635 |
0.19% 2741/4076 |
15.92% 2756/4524 |
0.47% 1981/4813 |
| 2024 | 12.15% 1268/3463 |
8.67% 173/2808 |
-0.60% 796/3014 |
12.57% 2320/3129 |
-7.77% 2793/3463 |
| 2023 | -6.93% 882/2656 |
2.40% 1361/2280 |
-5.13% 1378/2385 |
0.78% 344/2515 |
-4.94% 1218/2655 |
| 2022 | -18.36% 698/2207 |
-12.94% 671/1919 |
8.60% 349/2016 |
-14.82% 1156/2113 |
1.38% 1287/2208 |
| 2021 | -12.98% 1132/1822 |
-2.52% 660/1255 |
-1.96% 1184/1330 |
-10.35% 1221/1466 |
1.56% 876/1822 |
| 2020 | 43.82% 238/1250 |
-7.73% 565/1028 |
15.37% 507/1067 |
14.80% 256/1164 |
17.68% 113/1184 |
| 2019 | 51.11% 98/1092 |
30.94% 220/754 |
7.31% 11/804 |
2.39% 303/850 |
5.04% 757/918 |
| 2018 | -16.65% 111/834 |
- - |
- - |
- - |
-13.96% 563/691 |
| 2017 | 41.29% 26/714 |
- - |
- - |
- - |
- - |
| 2016 | -0.76% 112/605 |
- - |
- - |
- - |
- - |
| 2015 | 3.81% 229/575 |
- - |
- - |
- - |
- - |
| 2014 | 60.94% 30/237 |
- - |
- - |
- - |
- - |
| 2013 | -11.35% 162/186 |
- - |
- - |
- - |
- - |
| 2012 | 14.73% 14/140 |
- - |
- - |
- - |
- - |
| 2011 | -18.06% 20/102 |
- - |
- - |
- - |
- - |
| 2010 | -19.18% 52/58 |
- - |
- - |
- - |
- - |
| 2009 | 77.36% 20/27 |
- - |
- - |
- - |
- - |
| 2008 | -63.95% 19/26 |
- - |
- - |
- - |
- - |
| 2007 | 124.90% 16/22 |
- - |
- - |
- - |
- - |
| 2006 | 126.74% 4/14 |
- - |
- - |
- - |
- - |
| 2005 | -0.42% 2/11 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达上证50增强A VS. 长安沪深300非周期A(740101) |